Thursday 11 June 2020

The Brewery, London EC1


2012 Voting Panel


Mark Court


At Buchanan, Mark advises a wide range of healthcare clients on their communication requirements. He joined Buchanan in 2003 after a successful career in journalism on titles including The Times, where he was Health Industries Correspondent, the Sunday Telegraph, Daily Mail and Investors Chronicle. A science graduate of London University, Mark also holds a diploma from the London College of Communication.


Glyn Edwards

Summit plc

Glyn Edwards is CEO of Summit plc, Director of Oxford Cancer Biomarkers Limited and the National Cancer Research Institute and the interim Chief Executive Officer of the BioIndustry Association ("BIA"), a role from which he will step down shortly. He was previously Chief Executive Officer of Antisoma from 1998-2011 and prior to this he worked in a variety of business development roles in the biotech and healthcare industries. Mr Edwards has a BSc in Biochemistry from Bristol University and an MSc in Economics from the London Business School. Glyn was made a Member of the British Empire as recognition for his services to the biotechnology industry.



Stefan Hamill

Peel Hunt

Stefan joined Peel Hunt in January 2011, joining forces with Paul Cuddon to form what we believe is the strongest team in UK healthcare and life sciences. Prior to joining Peel Hunt, Stefan was a founder of independent research house Clear Capital (now part of Espirito Santo) where he covered a wide variety of firms across the sector and was ranked number three in Extel. Stefan was formerly a strategy consultant and has a PhD in antibody engineering from the University of Cambridge.


Anthony Hartley

Morgan Stanley

Dr Anthony Hartley is an Executive Director in the Healthcare Investment Banking Group at Morgan Stanley, where he focuses on pharmaceutical and biotechnology companies on a pan-European basis. Anthony has spent over ten years in healthcare investment banking, predominantly focused on the European biotech and pharmaceutical sectors, and has completed and advised on numerous M&A and corporate finance transactions in both the public and private biotech sectors. Before joining Morgan Stanley, Anthony previously worked for Lehman Brothers Europe and Credit Suisse First Boston. Anthony holds a Doctorate (D.Phil) in Pharmacology from The University of Oxford and an MBA (Distinction) from Manchester Business School.  Prior to his career in investment banking, Anthony spent a total of seven years in the pharmaceutical industry working in a variety of research and commercial roles at Pfizer, GlaxoSmithkline and AstraZeneca.



Oscar Izeboud

Kempen & Co

Oscar joined Kempen & Co, a merchant bank based in Amsterdam, the Netherlands, in 2006. He is currently Managing Director Corporate Finance, heading the Life Sciences/Healthcare team. Prior to this Oscar worked as Director Equity Research, covering European listed life sciences companies at Kempen & Co. Oscar has advised on a wide variety of primary and secondary public offerings and M&A transactions across Europe. Before Kempen & Co he worked in various commercial roles in the industry, eventually in business development at Crucell. Oscar obtained his PhD in Pharmacology at TNO in the Netherlands and he holds a MSc degree in Biopharmaceutical Sciences from the University of Leiden.



Michael King

Nomura Code Securities

Michael joined Nomura Code Securities in 2003 from WestLB Panmure, having moved from SG Securities in 2000. He has over 13 years' experience as a healthcare analyst and specialises in medical technology companies, although previously his coverage has also included the biotechnology and pharmaceutical sectors. Prior to joining SG Securities in 1997, Michael spent twelve years working in the medical technology industry, working for Amersham International (now GE Healthcare) and Pfizer Hospital Products, initially as a development scientist but mostly in international marketing. He graduated in 1985 with a degree in Biochemistry and Physiology from Southampton University.


Sarah Macleod


Sarah joined M:Communications as a Consultant in April 2012. She has over 16 years' experience in corporate and financial communications, ten of which have been focused exclusively on the healthcare sector. She has represented quoted and private companies from all over Europe and North America, from large caps to start-ups, and handled a wide range of fundraising and M&A transactions. Prior to M, Sarah gained in-house experience within a FTSE-250 company. Previous positions held include Director at MHP and Vice President at FTI.


Geraldine O'Keeffe

Life Sciences Partners

Geraldine O'Keeffe, Partner, joined LSP as a Senior Investment Manager in 2008. Prior to joining LSP, she held the position of senior sell-side analyst at Fortis, where she focused exclusively on the global biotechnology industry. While at Fortis, she initiated and maintained coverage on a wide range of biotechnology companies and was actively involved in several IPOs. Before joining the investment community, Geraldine worked for Biotrin (now part of Diasorin) and was instrumental in gaining FDA approval for several diagnostic tests. She also lectured in Biomedical Sciences for several years at the Dublin Institute of Technology. Geraldine has a BSc Biochemistry/Microbiology from University College Cork, an MSc in Biotechnology from University College Galway, Ireland and conducted post-graduate research at the Max Planck Institute for Biophysical Chemistry and Oxford University. She is also a graduate of The Dublin School of Business.



Gareth Powell

Polar Capital Technology Trust PLC

Gareth joined Polar Capital in 2007 to set up the healthcare team. He has over twelve years' investment experience in the healthcare sector, with ten years as a Portfolio Manager. He joined Framlington in 1999 becoming a portfolio manager on the Framlington Health fund. In 2002, he helped launch and then run the Framlington Biotech Fund. Gareth became a CFA charter holder in 2003. Gareth studied Biochemistry at Oxford from 1995 to 1999 and during that time worked at Astellas, the Sir William Dunn School of Pathology, the Wolfson Institute for Biomedical Research and the Oxford Business School.



 Ian Restall

Flathill Communications plc
Voting Panel Chairman

Throughout his career, Ian has been involved in the quoted growth companies sector. His early career was as a stockbroker, analyst, broadcaster and financial journalist in this area and since founding The Design Portfolio in 1991, he has been active in helping many companies in this sector with their investor communication and corporate reporting requirements. Ian is also President of The Design Portfolio Inc. and a member of the Investor Relations Society.



Nick Rodgers

IPSO Ventures plc

Nick is the CEO of technology commercialisation business IPSO Ventures and the founder of the Mediscience Awards dinner. Nick is an accountant and former investment banker with Beeson Gregory (later Evolution Securities). Nick is also the Chairman of Oxford BioMedica plc and a Non-executive Director of TMO Renewables Limited and Morvus Technology Limited.


Jonathan Senior

Nomura Code Securities

Jonathan joined Nomura Code in 2007. Previously, Jonathan was part of the healthcare corporate finance team at Credit Suisse and then a research analyst on the number one ranked biotech team. During his time at Credit Suisse, Jonathan was involved with the IPOs of NicOx, GPC Biotech and Actelion, as well as transactions for PowderJect, Oxford GlycoSciences and Galen. After leaving Credit Suisse, Jonathan joined Evolution Securities as a research analyst, where he was involved in fund raisings for Oxford BioMedica and Entelos. Prior to joining Credit Suisse, Jonathan was a doctor, with his final job before leaving medicine as a senior house officer in cardiac surgery at the John Radcliffe Hospital in Oxford. Jonathan studied Medicine at Lincoln College, Oxford and also holds a BA in Physiological Sciences.



Melanie Toyne-Sewell

College Hill Life Sciences

Melanie is a specialist in financial and corporate communications for Life Science companies and heads up Financial PR for the Life Sciences team. Prior to College Hill, Melanie was Head of Healthcare at the Hogarth Partnership, a partner in the Financial Dynamics Life Sciences team and a Director of Merlin Financial. She has extensive experience of capital market transactions and corporate issues facing the pharma, biotech, medtech and healthcare sectors. Before entering the field of financial PR, Melanie was at Price Waterhouse where she qualified as a chartered accountant. She has a BA Hons in Biochemistry from Oxford University.